|
Essel Propack (Emkay) Our prognosis of Ebidta margin not played out |
|
EPL’s Q1FY12 performance below expectations;Growth was primarily volume; AMESA and Americas report lower growth;Higher input cost and time lag in pass through tapered EBIDTA margins;Earnings revised downwards by 24.6% to Rs 4.2 per share for FY12E and by 16.5% to Rs 6.2 per share in FY13E | Date | Rating | Target Price | Recommendation Price | Broker house | | 29 Jul 2011 | buy | 63 | 43 | Emkay Report | |
|
essel propack (Angel) Profitable performance continues |
|
essel propack (Emkay) Subdued Quarter, Retain BUY |
EPL's Q4FY11 performance muted; misses revenue & PAT estimates; FY11 revenues grew 17%, led by strong volume growth; non-oral care in India and China report robust growth; Management guides 14% revenue growth - Americas & Europe to post recovery; rise in non-oral care share to also aid revenue growth; Eyeing Ebidta margin expansion of 200 bps - Quicker price pass through and Poland breakeven to be key drivers
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 5 May 2011 |
buy |
72 |
46 |
Emkay Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
essel propack (Emkay) Only Hiccups, Target Intact, Maintain BUY |
|
essel propack (Angel) Profitable performance continues |
|
Europe On Expected Lines; Maintain |
Name
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 29 Jul 2010 |
Buy |
57 |
48 |
Angel report |
links
Reports.DesiStockResearch.com |
